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were crossed to each other in plastic tubes at 25℃ to generate various genotypes of F 2 flies. Then, virgin male and female flies (F 2 generation) were separated immediately upon eclosion and kept in different vials. After that, single virgin male and female flies from the F 2 generation were mated with single virgin female and male flies of elav-GAL4 (driver line), respectively. After 48 h, parent flies were transferred to 18℃ in different tubes. Newly eclosed virgin male and female flies (F 3 generation) were collected in different tubes and used for genotyping. Genomic DNA from each Drosophila was isolated using DNAzol (Invitrogen, CA, USA) according to the manufacturer's instructions. The genotypes of the developed α-Syn/dOmi  and α-Syn/dOmi + lines were detected by PCR. Briefly, after the initial denaturation at 95℃ for 5 min, PCR was carried out by denaturation at 95℃ for 30 sec, annealing at 57℃ for 1 min to genotype α-Syn and dOmi+ or at 63℃ for 45 sec to genotype dOmi  and extension at 72℃ for 45 sec. After completion of 34 cycles, a final extension was carried out at 72℃ for 10 min. The PCR products were confirmed by agarose gel electrophoresis using Loading STAR (Dyne Bio, South Korea) and a 100-bp DNA ladder (Dyne Bio, South Korea). Primers for genotyping were as follows: αsynuclein F primer: 5'-TGT AGG CTC CAA AAC CAA GG-3'; α-synuclein R primer: 5'-GCT CCC TCC ACT GTC TTC TG-3'; dOmi + F primer: 5'-GGA AGA CTT AAC GCC AAC GA-3'; dOmi + R primer: 5'-GGC CGC TGA AGT CAA AG-3'; dOmi  F primer: 5'-AAG AAT TCC CGG TGT TAC ACA GTC ATG C-3'; dOmi  R primer: 5'-AGT CTA GAG GAT GTC TGA TCC ACG TCC T-3'.
Pan-neuronal and eye-specific expression of transgenes in Drosophila
Pan-neuronal expression of transgenes was achieved by crossing virgin female flies (driver line) carrying elav-Gal4 on their X chromosomes with transgenic flies. Eye-specific expression J o u r n a l P r e -p r o o f Journal Pre-proof of transgenes was achieved by crossing virgin female flies (driver line) carrying GMR-GAL4 on their X chromosomes with transgenic flies. These flies were maintained at 25 ℃ and, immediately after eclosion, sorted for Western blotting, immunohistochemistry and lifespan and locomotion assays.
Locomotion assay
Ten flies from each genotype were briefly anaesthetized with CO 2, placed in an empty 15-ml plastic tube, bunged with cotton wool, allowed to recover from CO 2 exposure for 30 min, gently tapped to the bottom of the tube and allowed to climb to a height of the 10-ml mark of the tube for 30 sec. The number of flies at the top (above the 10 ml mark) of the tube and the number of flies at the bottom (below the 2-ml mark) of the tube were recorded after 30 sec. Three trials were performed for each genotype at each time point. The performance index (PI) was calculated for 10 flies (an average of 3 trials) of each genotype using the formula PI = 0.5 × (n total + n top − n bottom )/n total , where n total is the total number of flies, n top is the total number of flies at the top, and n bottom is the total number of flies at the bottom (White et al., 2010) .
Lifespan assay 2.13. Histological analysis of Drosophila brains
Fly heads were dissected and fixed in 10% neutral-buffered formalin (Sigma-Aldrich, MO, USA) solution, embedded in paraffin, sectioned at 6 µm, de-paraffinized with xylene and ethanol, rehydrated with a descending series of diluted ethanol and permeabilized with PBS containing 1% Triton X-100 for 40 min at RT. After washing with PBST buffer (PBS with 0.20% Tween-20), antigen retrieval was performed with 10 mM sodium c itrate buffer (pH 6.0) for 20 min at 80 ℃ and blocked with 10% goat serum (Sigma-Aldrich, MO, USA) in PBS buffer containing 0.025% Triton X-100 and 1% BSA overnight at 4 ℃. After washing with PBST buffer and PBS buffer containing 0.025% Triton X-100, the tissue sections were double-stained with mouse anti-αsynuclein (ASy05; 1:300; Agricera antibodies, Sweden) and rabbit anti-dOmi antibodies (ab64111; 1:300; Abcam, UK) overnight at 4 ℃, followed by washing with PBST buffer and PBS buffer containing 0.025% Triton X-100. The sections were then incubated with 3% hydrogen peroxide (H 2 O 2 ) in PBS buffer containing 40% methanol for 30 min. After washing with PBST buffer, the sections were incubated with AlexaFluor 488-conjugated goat anti-mouse IgG (H + L) (1:500; Invitrogen, CA, USA) and AlexaFluor 568-conjugated goat anti-rabbit IgG (H + L) (1:500; Invitrogen, CA, USA) antibodies for 2 h at RT. After washing with PBST buffer, the slides were sealed with VectaMount permanent mounting medium (Vector Laboratories, CA, USA), and images were acquired with a Carl Zeiss LSM510 Meta confocal microscope. The stock solutions of primary and secondary antibodies were diluted in PBS buffer containing 2% goat serum, 1% BSA and 0.025% Triton X-100.
For immunohistochemical analysis, permeabilized brain sections were prepared as described above, and antigen retrieval was performed with 10 mM sodium citrate buffer (pH 6.0) for 20 J o u r n a l P r e -p r o o f min at 80℃. The sections were blocked with 3% H 2 O 2 in sodium phosphate buffer (NaP with 0.1% Triton X-100) containing 40% methanol for 30 min, washed with NaPT buffer and blocked again with 10% horse serum (Sigma-Aldrich, MO, USA) in NaP buffer containing 0.025% Triton X-100 and 1% BSA at RT for 4 h. After washing with NaPT buffer, the sections were then incubated with Avidin and Biotin solution (Vector Laboratories, CA, USA) for 30 min and washed with NaPT buffer. The sections were then incubated with mouse anti-α-synuclein antibody (ASy05; 1:100; Agricera antibodies, Sweden) and mouse anti-dOmi antibody (HTRA2; 1:100; Antibodies-online GmbH, Germany) overnight at 4℃, followed by washing with NaPT buffer. After that, the sections were incubated with horse anti-mouse IgG (H+L) antibody (1:100;
Vector Laboratories, CA, USA) for 2 h and washed with NaPT buffer. The antibody-treated slides were incubated with premixed VECTASTAIN ABC reagent (Vector Laboratories, CA, USA) for 40 min at RT and washed with NaPT buffer. The slides were incubated with DAB substrate (Vector Laboratories, CA, USA) in water for 3~5 min until the desired stain intensity developed and then rinsed with water. To counterstain, 1~2 drops of haematoxylin QS (Vector Laboratories, CA, USA) were briefly applied to the sections and rinsed with running tap water.
Finally, the sections were mounted with VectaMount permanent mounting medium (Vector Laboratories, Burlingame, CA, USA), and images were taken by slide scanner microscopy using an Aperio ScanScope FL (Leica Biosystems, Wetzlar, Germany). The stock solutions of primary and secondary antibodies were diluted in NaP buffer containing 2% horse serum, 1% BSA and 0.025% Triton X-100.
Preparation of Drosophila brain homogenates
J o u r n a l P r e -p r o o f Journal Pre-proof Fly heads were dissected, placed in Eppendorf tubes, and TM buffer containing 0.1% SDS from the total protein extraction kit (Millipore, MA, USA) was added at a volume of 3 µl per head. Samples were sonicated for 6 min at 4 ℃, incubated on ice for 5 min and centrifuged at 17,000 x g for 1 min at 4℃. The supernatant was collected and centrifuged again at 17,000 x g for 3 min at 4℃, and the final supernatant was collected. Protein concentrations of both homogenates were determined using the BCA protein assay kit (Sigma-Aldrich, MO, USA).
Total protein extracts of equal amounts from each sample were subjected to Western blot analysis with mouse anti-α-synuclein antibody (4D6) and mouse anti-dOmi antibody (HTRA2).
Light microscopy and scanning electron microscopy of the Drosophila eye
Adult male and female flies of each genotype were collected in an Eppendorf tube at 10 and 40 days post-eclosion and anaesthetized with CO 2 , frozen at 80℃ for 1 h, mounted on their sides. The eyes were then examined with a light microscope (AmScope, UK). For scanning electron microscopy studies, flies were dehydrated in an ascending series of 30%, 40%, 50%, 60%, 70%, 80%, 90% and 100% ethanol solutions for 10 min at RT. Then, flies were air dried and mounted on black tape on a slide with one eye upward using colloidal graphite in an isopropanol base. After that, flies were coated in Osmium tetroxide, air dried, and placed on a rotating platform to permit orientation under vacuum, and images were captured using a JSM-6400 scanning electron microscope (JEOL Ltd., Tokyo, Japan).
For haematoxylin & eosin (H&E) staining, fly heads were dissected, fixed in 10% neutralbuffered formalin solution (Sigma-Aldrich, MO, USA), embedded in paraffin and sectioned at 6 µm. Deparaffinization was performed by washing with hot water, air drying and baking J o u r n a l P r e -p r o o f overnight at 65℃. The sections were stained with haematoxylin and eosin, and eye images were acquired by slide scanner microscopy using a Aperio ScanScope FL (Leica Biosystems, Germany) (Chung et al., 2016; Chung et al., 2018) .
Statistical analysis
All statistical analyses were presented as the mean ± SEM, and the significance was calculated using one-way ANOVA followed by Bonferroni/Tukey multiple tests for individual means using IBM SPSS statistics 21 software. P values less than 0.05 were considered statistically significant. P values were indicated as follows: *p < 0.05; **p < 0.01; and ***p < 0.001. The intensity of oligomeric α-synuclein was analysed using ImageJ software.
Results

Omi specifically recognizes and precisely degrades oligomeric α-synuclein
Extensive in vivo and clinical results suggested that Omi is associated with PD (Jones et al., 2003; Martins et al., 2004; Strauss et al., 2005) . These results lead to the hypothesis that Omi degrades neurotoxic oligomeric α-synuclein, bestowing a neuroprotective function by acting on α-synuclein-associated neurodegeneration. To investigate the enzymatic characteristics of Omi, recombinant human Omi (hOmi) was produced and purified from E. coli BL21 (DE3) pLysS-pET28a + , and tested for its catalytic activity against α-synuclein ( Fig. 1 ). The incubation of hOmi with oligomerized α-synuclein containing a mixture of monomers and oligomers resulted in precise removal of oligomeric α-synuclein but not monomeric α-synuclein at all tested temperatures ( Fig. 1A, Fig. S1 ). The results in Fig. 1 , however, could be derived by either J o u r n a l P r e -p r o o f Journal Pre-proof oligomeric α-synuclein-specific degradation or by chaperone activity of Omi on oligomeric αsynuclein to re-establish its monomeric form. To test these possibilities, only oligomers were isolated from oligomerized α-synuclein using a size-exclusion column (Fig. S2) , and subsequent treatment of hOmi completely degraded the purified oligomeric α-synuclein but not monomeric α-synuclein ( Fig. 1B, Fig. S1 ). This result clearly indicates that Omi specifically recognizes and precisely degrades oligomeric α-synuclein.
Since Omi is known to be associated with PD, it would be interesting to investigate if Omi mutation can degrade oligomeric α-synuclein. As expected, the specific degradation of oligomeric α-synuclein was completely abolished upon introduction of the S306A mutation of Omi (Fig. 1C, Fig. S1 ). This experiment clearly shows that the proteolytic activity of Omi on oligomeric α-synuclein is linked to the serine at position 306 in Omi. This result further implies how Omi can bestow its neuroprotective function on neurons as well as its molecular mechanism in PD.
The next important issue regarding the precise degradation of oligomeric α-synuclein by Omi is the functional role of Omi domains. The protease domain of Omi in which the PDZ domain was deleted from Omi (OmiΔPDZ) was subcloned for functional analysis. An enzymatic assay confirmed that the OmiΔPDZ domain alone was able to degrade oligomeric α-synuclein ( Fig. 1D,   Fig. S1 ). In fact, the protease activity of the OmiΔPDZ domain on oligomeric α-synuclein was much stronger than that of intact Omi. In addition to degrading oligomers, OmiΔPDZ showed slight protease activity for monomeric α-synuclein at 37℃, with protease activity increasing along with temperature elevation until the denaturation of Omi, indicating that the OmiΔPDZ domain has strong non-specific protease activity. The X-ray crystal structure of Omi revealed J o u r n a l P r e -p r o o f Journal Pre-proof that the PDZ domain is flexibly bound to the loop between β5 and β6 in the OmiΔPDZ domain, probably to restrain its protease activity. These experimental data, along with the structural characteristics of Omi, suggest that the PDZ domain of Omi functions as a specific recognition domain for oligomeric α-synuclein.
The function of Omi in resolving α-synuclein-induced neurotoxicity is evolutionarily conserved
We isolated the degradation product of oligomeric α-synuclein by Omi to identify the cleavage site of oligomeric α-synuclein by Omi. N-terminal Edman sequencing of the degraded product of oligomeric α-synuclein showed that the cleavage site of oligomeric α-synuclein was located between V82 and E83 within the hydrophobic NAC domain of α-synuclein ( Fig. 2A) .
Interestingly, the cutting site of oligomeric α-synuclein by Omi is the hydrophobic NAC domain of α-synuclein, similar to the case of bacterial Omi (HtrA), which cuts the amino acid sequence of the hydrophobic domain. This result indicates that the enzymatic mechanism of Omi has been evolutionarily conserved from bacteria to humans.
Because enzymatic studies showed that Omi functions as a very specific protease to precisely degrade oligomeric α-synuclein, the protection of neurons by Omi was further tested in the brains of mnd2 mice, which are Omi-null mutant mice that develop PD. The incubation of hOmi with mouse brain extracts of homozygous mnd2, heterozygous mnd2 and wild-type mice revealed the absence of any noticeable proteolytic degradation in all tested groups (Fig. 2B left,   Fig. S3 ), indicating that Omi is not a general but rather a highly specific protease. Western blotting of the gel with anti-α-synuclein (4D6) confirmed the accumulation of a large quantity of oligomeric α-synuclein in mnd2/mnd2 mice, unlike wild-type littermate controls ( Fig. 2B right, J o u r n a l P r e -p r o o f Journal Pre-proof Fig. S3 ). Because some studies have suggested that oligomeric α-synuclein is the toxic species which is responsible in the pathogenesis of PD (Breydo et al., 2012; Wan and Chung, 2012; Ingelsson, 2016) , the massive accumulation of oligomeric α-synuclein in mnd2/mnd2 mice can contribute to PD. Incubation of hOmi with total protein extract from mnd2 mice, however, resulted in complete degradation of α-synuclein oligomers without affecting monomers (Fig. 2B,   Fig. S3 ). This result indicates that the absence of Omi in mnd2/mnd2 mice results in unsuccessful removal of oligomeric α-synuclein, a suggested cause of PD. Overall, these experiments confirm the precise oligomeric α-synuclein-specific degradation activity of Omi.
After in vitro confirmation of the neuroprotective function of Omi in oligomeric α-synucleininduced neurotoxicity, we next aimed to investigate the etiopathogenic mechanism of Omi in vivo using Drosophila. First, the enzymatic characteristics of Omi in Drosophila melanogaster (dOmi) were tested. dOmi (93~422 amino acids) was produced in E. coli BL21 (DE3) pLysS-pET28a+dOmi, and tested with α-synuclein. The incubation of dOmi with oligomerized αsynuclein containing a mixture of monomers and oligomers resulted in precise removal of oligomeric α-synuclein without affecting monomers at all tested temperatures (Fig. S4 ). As expected, dOmi treatment on monomeric and purified oligomeric α-synuclein resulted in precise degradation of oligomeric α-synuclein without affecting monomeric α-synuclein (Fig. 2C ). This result indicates that resolution of α-synucleininduced neurotoxicity by Omi is evolutionarily conserved. The in vitro experimental results of oligomeric α-synuclein-specific degradation by Omi ( Fig.   1 and 2) prompted us to investigate the in vivo role of Omi in PD. Although Drosophila models are a robust method to investigate the etiopathogenic role of a gene in human diseases, there is a limitation in investigating gene-to-gene interactions using Drosophila models. Genotyping in Drosophila inevitably requires sacrificing flies, unlike genotyping in mice, which requires only tail blood. To overcome this barrier, we developed an in vivo assay system of dual gene interaction, with which we established the α-Syn/dOmi  Drosophila melanogaster and the α-Syn/dOmi + Drosophila melanogaster lines ( Fig. S5 and S6) . The α-Syn/dOmi  Drosophila line pan-neuronally expresses α-synuclein under knockout of dOmi, and the α-Syn/dOmi + Drosophila pan-neuronally coexpresses α-synuclein and dOmi.
Pan-neuronal expression of Omi rescues α-synuclein-induced neurotoxicity in a
Since the Parkinsonism phenotype of the α-Syn Drosophila PD model is characterized by locomotor defects accompanied by reduced survivability (Feany and Bender, 2000; Muñoz-Soriano and Paricio, 2011; Nagoshi, 2018) , locomotor defects and survivability were tested using the dual gene interaction model to assess the effect of dOmi on α-synucleininduced αsynuclein-induced neurotoxicity (Fig. 3 ). Without interaction with α-synuclein, the knockout of dOmi or expression of dOmi did not cause a difference in the loss of climbing ability compared to that of wild-type controls (elav-GAL4) ( Fig. 3A and B) . In a dual gene interaction model, however, the performance index of locomotion of α-Syn/dOmi  Drosophila was significantly lower than that of α-Syn Drosophila but was rescued completely by the expression of dOmi in α-Syn/dOmi + Drosophila (Fig. 3A and B ). Survivability was not significantly different in dOmi  Drosophila and dOmi + Drosophila compared to in wild-type controls (Fig. S7) . In contrast, survivability was significantly increased in α-Syn/dOmi + Drosophila compared to in α-Syn
J o u r n a l P r e -p r o o f
Drosophila and α-Syn/dOmi  Drosophila (Fig. S7 ). This result indicates that a lack of dOmi exacerbates α-synucleininduced neurotoxicity and that dOmi plays a neuroprotective role by reducing the toxicity of α-synuclein in the etiopathogenesis of PD (Fig. S7) .
Omi rescues α-synuclein-induced neurotoxicity by precisely degrading oligomeric αsynuclein in a Drosophila model of PD
To investigate how Omi rescues α-synucleininduced neurotoxicity in Drosophila, histological examinations were performed on the brains of wild-type control (elav-GAL4) and transgenic (dOmi  , dOmi + , α-Syn, α-Syn/dOmi  and α-Syn/dOmi + ) Drosophila.
Immunohistochemical confocal microscopy using an oligomeric α-synuclein-specific monoclonal antibody, anti-α-Syn (ASy05), on brain sections showed that co-expression of dOmi and α-synuclein eliminated oligomeric α-synuclein (Fig. 4) , consistent with in vitro experiments ( Fig. 1 and 2) . Quantification of the green fluorescent intensity in the brain sections clearly revealed a large quantity of oligomeric α-synuclein accumulation in α-Syn Drosophila and a greater accumulation in α-Syn/dOmi  Drosophila (Fig. 4A and B) . In α-Syn/dOmi + Drosophila, however, only trace amounts of α-synuclein oligomers were detected. We further confirmed the degradation of α-synuclein by dOmi in total protein extracts of the brain (Fig. 4C, Fig. S8 ).
Western blotting with an anti-α-synuclein antibody (4D6) showed that both monomeric and oligomeric α-synuclein accumulated in the brains of α-Syn Drosophila as well as in α-functions as an aetiological agent in PD and that monomeric α-synuclein lacks neurotoxicity and plays an essential role in maintaining a supply of synaptic vesicles in presynaptic terminals (Bellani et al., 2010; Scott and Roy, 2012; Burré, 2015) , this result sheds light on how Omi provides neuroprotection in PD.
The histological features of Drosophila brains were observed after immunostaining with antiα-synuclein as well as with anti-Omi antibodies (Fig. 5 ). We found that pan-neuronal expression of α-synuclein clearly caused the accumulation of α-Syn which was similar with Lewy bodies in α-Syn/dOmi  Drosophila to a greater degree than in α-Syn Drosophila but not greater than in the brains of α-Syn/dOmi + Drosophila (Fig. 5, Fig. S9 ). In accordance with the previous results that Omi precisely degrades oligomeric α-synuclein, this result again confirms that dOmi rescues α-synucleininduced neurotoxicity in a Drosophila model of PD.
Omi counteracts α-synuclein-induced developmental defects in the Drosophila eye
It has been previously observed that the expression of α-synuclein in developing eyes causes retinal degeneration in Drosophila (Haywood and Staveley, 2004; M'Angale and Staveley, 2012; Xiong and Yu, 2018) . α-synucleininduced retinal degeneration well represents α-synucleininduced neurotoxicity and would provide additional evidence for Omi's role in protection from α-synucleininduced neurotoxicity. To test this, we crossed the GMR-GAL4 driver line with each of the experimental Drosophila lines to drive the expression of each transgene in the ommatidial unit. The eye-specific expression of α-synuclein clearly showed degenerated retina ( Fig. 6) . At 40-days-old, α-Syn Drosophila showed substantial vacuolar changes, indicating that α-synuclein acted as an aetiological agent for retinal degeneration. At the same time, retinal J o u r n a l P r e -p r o o f Journal Pre-proof degeneration was exacerbated in the eyes of α-Syn/dOmi  Drosophila, while there was very little, if any, degeneration of the eyes of α-Syn/dOmi + Drosophila (Fig. 6A) .
Additionally, the expression of α-synuclein led to developmental defects of the eyes, such as a loss of general retinal tissue integrity and roughness of the eye. Serious eye defects were observed in both male and female α-Syn Drosophila, and they become more serious with increasing age. This eye defect was exacerbated in α-Syn/dOmi  Drosophila. In contrast to α-Syn Drosophila and α-Syn/dOmi  Drosophila, there was no eye defect in α-Syn/dOmi + Drosophila, which were almost equivalent to the wild-type controls (GMR-GAL4) (Fig. 6B) .
Scanning electron microscopy also revealed serious defects in the eyes of α-Syn Drosophila with more serious damage in α-Syn/dOmi  Drosophila, while α-Syn/dOmi + Drosophila exhibited normal eyes without any noticeable damage (Fig. 6C) . Furthermore, the bristle of the eye became lost as α-Syn Drosophila aged, and this was exacerbated in α-Syn/dOmi  Drosophila. However, the bristle of the eye of α-Syn/dOmi + Drosophila was similar to that of normal wild types (GMR-GAL4) (Fig. 6D) . Similarly, ommatidial disarray was significantly increased in α-Syn Drosophila and exacerbated in α-Syn/dOmi  Drosophila, while that of α-Syn /dOmi + Drosophila was similar to that of normal wild types (GMR-GAL4). The difference became more evident as flies aged (bottom panel of Fig. 6C and D) . This result clearly demonstrates the neuroprotective role of Omi in α-synucleininduced neurodegeneration.
Discussion
The most commonly manifested pathophysiological feature of dopaminergic neurons of PD is an abnormal accumulation of oligomeric α-synuclein in the form of Lewy bodies and Lewy J o u r n a l P r e -p r o o f neuritis in neurons (Baba et al., 1998; Spillantini et al., 1998; Schulz-Schaeffer, 2010) . Normally, monomeric α-synuclein performs its biological function in neurons as a presynaptic protein that plays an important role in maintaining a supply of synaptic vesicles in presynaptic terminals (Bellani et al., 2010; Scott and Roy, 2012; Burré, 2015) . However, the monomeric form of αsynuclein is naturally prone to aggregated into oligomers or fibril by adopting a β-sheet conformation which is very toxic to neurons (Luk et al., 2012; Alderson and ley, 2013; Patterson et al., 2019; Zhang et al., 2018) . The neurotoxicity of oligomeric α-synuclein has been intensively investigated for decades, and it is now generally accepted that blocking oligomeric αsynuclein-induced neurotoxicity is an ideal target for the development of therapeutic age nts for PD. By developing an in vivo model of dual gene interaction using Drosophila, we proved that Omi specifically recognizes and precisely degrades oligomeric, but not monomeric α-synuclein to prevent from oligomeric α-synucleininduced neurotoxicity, implying that blockage of oligomeric α-synucleininduced neurotoxicity by Omi could be a critical target for drug development for PD.
After the identification of abnormal accumulation of oligomeric α-synuclein in Lewy bodies and Lewy neuritis, a catabolic pathway of oligomeric α-synuclein in neurons have been actively investigated. The ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) have been recognized as possible mechanisms for the degradation of oligomeric αsynuclein (Webb et al., 2003; Pan et al., 2008) . However, both the UPS and ALP are general intracellular proteolytic pathways for the degradation of wasted proteins in cells without any selectivity towards oligomeric α-synuclein (Cook and Petrucelli, 2009; Wang and Wang, 2015) .
Additionally, these pathways degrade monomeric α-synuclein. Considering these characteristics of the UPS and ALP, proteolytic degradation of α-synuclein by the UPS and ALP cannot play a J o u r n a l P r e -p r o o f Journal Pre-proof critical role in the pathogenesis of PD, excluding the UPS and ALP as potential therapeutic targets for PD. Surprisingly, oligomeric α-synuclein is resistant to all proteases, including proteinase K (Neumann et al., 2002; Abd-Elhadi et al., 2015) , and the clearance mechanism for α-synuclein remains unknown. Our results show that Omi precisely removes the causative agent of PD, i.e., oligomeric α-synuclein in neurons. In that sense, the precise oligomer-specific degradation by Omi provides a strong candidate for the development of therapeutic agents for PD.
Omi is a homologue of the bacterial heat shock protein HtrA, which specifically recognizes and degrades denatured proteins to protect bacteria (Lipinska et al., 1988; Clausen et al., 2002; Liu et al., 2009) . Omi is well conserved evolutionarily with respect to its amino acid sequence and three-dimensional structure (Liu et al., 2009 ). Both Omi-knockout mice and loss-of-function Omi mutant mice have shown that Omi plays a neuroprotective role in preventing PD (Jones et al., 2003; Martins et al., 2004) . In concordance with these findings, overexpression of Omi in the brains of mice (Saito et al., 2004; Liu et al., 2007) and Drosophila (Chung et al., under review) suggest a neuroprotective role of Omi. It should also be noted that mutations in Omi have been found in PD patients (Strauss et al., 2005; Abou-Sleiman et al., 2006; Henchcliffe and Beal, 2008; Krüger et al., 2011) . Considering that the bacterial function of HtrA is to degrade misfolded proteins through its proteolytic activity (Cassone et al., 2012) , it is very interesting to note that the function of Omi to degrade and remove denatured proteins, e.g., oligomeric α-synuclein, is evolutionarily conserved in animals. Although mammalian Omi is a nuclear encoded serine protease containing a mitochondrial targeting sequence (MTS) which mediates its import into mitochondria from cytosol, confocal immunofluorescence imaging analyses on both primary cortical neurons and neuronal cell lines has been showed that Omi is localized to both J o u r n a l P r e -p r o o f Journal Pre-proof mitochondria and cytosol (Liu et al., 2009) . Considering the fact that mitochondrial dysfunctions as well as Lewy bodies in cytosol are observed as the pathological hallmark in PD pathogenesis (Henchcliffe and Beal, 2008) , the cellular location of Omi again support a neuroprotective role of Omi in PD.
The presence of mutations/polymorphisms in Omi in sporadic PD patients as well as animal experiments confirmed the association of Omi with PD, naming Omi as PARK13 to represent a PD gene (Strauss et al., 2005; Krüger et al., 2011) . Also, observation of widespread accumulation of Omi in Lewy bodies in the brains of PD patients further solidified a possible association of Omi with PD (Kawamoto et al., 2008) . However, both the molecular mechanism of Omi in PD and its interaction with other PD-related genes have remained unknown. This work elucidated not only the molecular mechanism of Omi in PD but also the etiopathogenic mechanism of PD. The etiopathogenic mechanism of currently known PD-causing genes can be grouped into two pathways: disruption of PINK1-associated phosphorylation in mitochondria and neurotoxic protein aggregation associated with α-synuclein. Both in vitro and genetic studies show that Omi functions downstream of PINK1 (Plun-Favreau et al., 2007; Todd and Staveley, 2008; Tain et al., 2009) . In this study, we showed that Omi specifically recognizes and precisely removes oligomeric α-synuclein, providing a key piece of the PD puzzle by linking these two PD etiopathogenic pathways at the molecular level. 
